Liia D. Vainchtein

Carcinogen and Anticancer Drug Transport by Mrp2 in Vivo: Studies Using Mrp2 (Abcc2) Knockout Mice

Maria L.H. Vlaming, Karin Mohrmann, Els Wagenaar et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 155 citations

A new, validated HPLC‐MS/MS method for the simultaneous determination of the anti‐cancer agent capecitabine and its metabolites: 5′‐deoxy‐5‐fluorocytidine, 5′‐deoxy‐5‐fluorouridine, 5‐fluorouracil and 5‐fluorodihydrouracil, in human plasma

Liia D. Vainchtein, Hilde Rosing, Jan H.M. Schellens et al. · Biomedical Chromatography · 2009 · 68 citations

Chemoprevention Strategy, Hplc System, Pre-clinical Pharmacology +23

Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy

Markus Joerger, Alwin D. R. Huitema, Henk Boot et al. · Cancer Chemotherapy and Pharmacology · 2015 · 54 citations

Gastrointestinal Oncology, Medicine, Capecitabine-based Chemotherapy +8

A simple and sensitive assay for the quantitative analysis of paclitaxel and metabolites in human plasma using liquid chromatography/tandem mass spectrometry

Liia D. Vainchtein, Bas Thijssen, Ellen Stokvis et al. · Biomedical Chromatography · 2005 · 46 citations

Metabolomic Profiling, Hplc System, Pharmacotherapy +20

Validated assay for the simultaneous determination of the anti‐cancer agent gemcitabine and its metabolite 2′,2′‐difluorodeoxyuridine in human plasma by high‐performance liquid chromatography with tandem mass spectrometry

Liia D. Vainchtein, Hilde Rosing, Bas Thijssen et al. · Rapid Communications in Mass Spectrometry · 2007 · 37 citations